Written by Seamus Kelleher.
Roughly eight million people rush to hospital emergency rooms each year due to chest pain, the second leading cause of ER trips in the United States. The pain is often a sign of a more serious underlying cardiac issue, so it’s critical that first responders and medical professionals get accurate information quickly. Currently, electrocardiograms (ECGs or EKGs) are used to provide a snapshot of a heart’s rate and rhythm, but they are often inaccurate or incomplete in identifying the source of discomfort. Genetesis in Cincinnati, Ohio, has developed an innovative 3D heart mapping tool using magnetic fields to accurately diagnose, characterize and guide the treatment of cardiac disorders.
“Most cases of chest pain aren’t actually cardiac related at all, but that’s difficult to determine using today’s technology,” said Peeyush Shrivastava, Genetesis’ CEO. “Without painful injections, radiation or even patient contact, we can provide a detailed, 3D map of a heart and identify possible abnormalities.”
The company’s CardioFlux™ technology uses biomagnetic sensors to analyze natural magnetic outputs of the heart, and then software algorithms identify any abnormal areas of activity. In layman’s terms, the heart emits electrical activity. Measuring this activity can indicate unusual or problematic activity, and mapping it in 3D helps pinpoint the location. This information may drive safer, more accurate diagnoses and treatment of cardiac issues such as myocardial ischemia, atrial fibrillation, ventricular tachycardia and a variety of other cardiac arrhythmias.
“I’ve always been a tinkerer, big nerd stuff, and was always interested in the electrical nature of the heart,” said Shrivastava. “When I discovered there was no easy way to measure this electrical current in a clinical environment, I wanted to solve that problem with my friends in Mason, Ohio. Fast-forward a couple of years and we’re still at it.”
Genetesis has attracted the attention and support of industry leaders, most notably Mark Cuban of Dallas Mavericks and Shark Tank fame. After Shrivastava sent a cold pitch email to Cuban’s personal Gmail account, the billionaire investor took notice, joined as an advisor to the young company and eventually made a significant investment through his company, Radical Investments. His engaged, active mentorship and extensive experience helped Genetesis navigate the tricky, unfamiliar waters of building a company.
Genetesis recently closed a funding round with a lead investment from CincyTech, a southwest regional partner of Ohio Third Frontier. Shrivastava says these funds are instrumental in scaling engineering efforts, launching additional clinical studies and seeking regulatory clearance from the FDA. He says Genetesis is poised to make a name for itself in the world of medical technology.
“There’s a real medical tech corridor in Cincinnati and in Mason and we want to be a part of that. Our technology has massive implications and brings something unique to the table,” said Shrivastava. “We’ll continue to grow our diverse, talented team right here and contribute to the growth of medical technology in Ohio.”